Welcome to our dedicated page for Owens & Minor SEC filings (Ticker: OMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Owens & Minor, Inc. (historically NYSE: OMI) provide detailed documentation of the company’s transformation into Accendra Health, Inc. and its strategic focus on home-based care. Forms 8-K describe key events such as the entry into and completion of the Equity Purchase Agreement for the sale of the Products & Healthcare Services (P&HS) segment, the structure of the consideration received, and the company’s retained equity interest in the divested business. These filings also outline related credit facility amendments, receivables sale programs, and the release of certain subsidiaries from guarantees under term loan and note indentures.
Investors can use this filings page to access current and historical 8-K reports that explain material events, including transaction terms, transition services arrangements, and changes to executive compensation and retirement plans. The filings also document the name change from Owens & Minor, Inc. to Accendra Health, Inc. through Articles of Amendment and amended bylaws, and they state that the company expects its common stock to begin trading on the New York Stock Exchange under the ticker symbol ACH. These disclosures clarify how the legacy OMI symbol relates to the continuing entity.
Quarterly and annual reports (Forms 10-Q and 10-K, when accessed through EDGAR) provide more comprehensive information about the company’s segments, including the classification of the P&HS segment as discontinued operations and the description of continuing operations as primarily representing the Patient Direct segment and certain functional operations. They also include discussions of risk factors, capital structure, and accounting treatment of receivables sale arrangements.
On Stock Titan’s SEC filings page, users can review these documents as they are made available from EDGAR and take advantage of AI-powered tools that summarize complex disclosures. These tools can help highlight the implications of major transactions, the impact of the P&HS divestiture on the company’s financial statements, and the significance of the corporate name and ticker change for holders of the legacy OMI shares.
Accendra Health, Inc., formerly Owens & Minor, Inc., filed an amended current report to update the financial information related to the previously completed sale of its P&HS business. The amendment is limited to revising Item 9.01 to include unaudited pro forma condensed financial information reflecting the impact of this transaction.
This pro forma information is provided as Exhibit 99.1 and is incorporated by reference, helping readers see how the company’s results would look after the P&HS business sale under the Equity Purchase Agreement with Dominion Healthcare entities. No other parts of the earlier closing report are changed.
Owens & Minor, Inc. completed the sale of its Products & Healthcare Services (P&HS) business to Dominion Healthcare for $375 million in cash, subject to adjustments, plus rollover equity in the buyer’s parent. The company also put in place an amended receivables sale program under which up to $150 million of accounts receivable can be sold on a limited‑recourse basis and accounted for as true sales, removing those receivables from its balance sheet. In connection with the divestiture, certain subsidiaries were released as guarantors under existing credit facilities and indentures, two senior executives departed, and the executive deferred compensation plan was amended for affected employees. The company is changing its corporate name to Accendra Health, Inc., with NYSE trading expected to begin under the new name and ticker “ACH” on January 2, 2026.
Owens & Minor, Inc. reports two key corporate actions. The board approved an amendment to the Owens & Minor Executive Deferred Compensation and Retirement Plan that will freeze participation and all contributions for all participants, effective January 1, 2026. This means executives already in the plan will not be able to make additional deferrals under this program after that date.
The company also plans a rebrand. It announced that it will change its name to Accendra Health, Inc. and that its New York Stock Exchange ticker symbol will change from “OMI” to “ACH.” The name change is anticipated to be effective on or about December 31, 2025, with trading under the new name and ticker expected to begin on or about January 2, 2026.
Owens & Minor, Inc. announced leadership changes focused on operations and human resources. Effective December 5, 2025, the company appointed Perry A. Bernocchi, age 67, as Executive Vice President and Chief Operating Officer. He has served since March 2023 as Executive Vice President and Chief Executive Officer of the company’s Patient Direct segment, and his compensation and employment terms remain unchanged.
The company also disclosed that Jennifer Stone, Executive Vice President and Chief Human Resources Officer, will leave effective December 31, 2025. Upon her departure, the CHRO position will be eliminated, and Heath Galloway, Executive Vice President, General Counsel & Corporate Secretary, will assume oversight of the human resources function in addition to his current responsibilities.
Owens & Minor, Inc. reported that its management team will participate in two upcoming investor conferences. The company has prepared an investor presentation specifically for the Bank of America Leveraged Finance Conference and has made both the related press release and the presentation available as exhibits. These materials are being furnished, not filed, which means they are provided for informational purposes and are not incorporated into other securities law filings unless specifically referenced.
Owens & Minor, Inc. (OMI) executive share transfer reported. On 11/19/2025, EVP and CEO, Patient & Health Services, Andrew G. Long transferred 47,908 shares of Owens & Minor common stock to a family trust in a transaction coded "G" (a gift) at a reported price of $0 per share.
Following the transaction, he directly held 214,064 shares of common stock and indirectly held 234,361 shares through the Long Family Trust. The trust is described as one for which he is a trustee, and he and a member of his immediate family are the sole beneficiaries.
Owens & Minor (OMI): Coliseum Capital filed a Schedule 13D, replacing its prior 13G and signaling a more active posture. The reporting group—Coliseum Capital Management, Coliseum Capital, Coliseum Capital Partners, and principals Adam Gray and Christopher Shackelton—disclosed beneficial ownership of 13,100,807 shares, representing 16.9% of the common stock.
Coliseum states the stake was acquired for investment purposes and outlines potential actions under Item 4, including discussions with management and other stakeholders and evaluating proposals related to operations, governance, capitalization, business combinations, asset sales, or financing transactions. As context, Coliseum Capital Partners is the record owner of 10,657,337 shares and a separate account managed by Coliseum holds 2,443,470 shares. Shares outstanding were 77,346,594 as of October 24, 2025. The group reported no transactions in the 60 days preceding this filing.
Owens & Minor (OMI) filed its Q3 2025 10‑Q, highlighting modest growth in continuing operations but large losses tied to the pending divestiture of its Products & Healthcare Services (P&HS) segment. Net revenue from continuing operations was $697,264 for the quarter, up slightly from $686,846. Continuing operations posted an operating income of $26,470, but interest and other items drove a loss before taxes of $(3,635).
The company recorded a Q3 net loss of $(150,276), largely due to discontinued operations. Year‑to‑date, the net loss reached $(1,044,316), reflecting a $771,640 loss on classification of P&HS as held‑for‑sale and a $106,389 goodwill impairment. OMI also paid an $80,000 transaction breakage fee for terminating a prior acquisition.
On October 7, 2025, OMI signed an agreement to sell P&HS for $375 million in cash, retain a 5% equity interest, and included termination fees of $9.4 million or $19 million; closing is expected in the first quarter of 2026, subject to customary approvals. As of September 30, 2025, total debt was $2,115,261 with $270,700 drawn on the revolver and $280,000 due within twelve months. Equity swung to a deficit of $(429,507). Concentration risk rose as the largest commercial payor plans to terminate contracts representing $242,000 (12%) of nine‑month net revenue, including $173,000 of capitation revenue.
Owens & Minor (OMI) furnished materials related to its results of operations. The company issued a press release covering financial results for the third quarter and nine months ended September 30, 2025, and made an earnings presentation available on its investor relations website.
Both documents were furnished, not filed, under Items 2.02 and 7.01, respectively, and are included as Exhibits 99.1 and 99.2. As furnished materials under General Instruction B.2, they are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 5,962,847 shares of Owens & Minor (OMI) common stock, representing 7.71% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 739,487 with shared voting power. It has 5,153,718 shares with sole dispositive power and 809,129 with shared dispositive power. The filer is classified as an investment adviser (IA) and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.